HIV Infections Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Exploring the Safety, Tolerability, and Antiviral Effect of Substituting 600 mg Racivir for 3TC in HIV-Infected Subjects Who Have the M184V Mutation and Are Currently Failing on a HAART Regimen Containing Lamivudine
Racivir ® (RCV) is an experimental drug which means it is not approved for use by the United
States Food and Drug Administration (FDA), but it can be used in research studies like this
one. RCV (Racivir®) is part of a class of drugs known as "Nucleoside Reverse Transcriptase
Inhibitors" (NRTIs), which are intended to block a further increase in the amount of HIV
virus in the body. Laboratory research suggests that RCV (Racivir®) may be effective in
patients who have developed resistance to other NRTIs, particularly 3TC (lamivudine,
Epivir®). However, a study of RCV (Racivir®) has not been done with patients who have
previously been treated with other HAART (Highly Active Antiretroviral Therapy -- taking
multiple HIV drugs at once) medications including 3TC (lamivudine, Epivir®).
The purpose of this study is to evaluate the safety and effectiveness of RCV (Racivir®) when
used together with other HIV drugs in people who have previously been treated with 3TC
(lamivudine, Epivir®) and are failing with their current HAART treatments. This study will
include a total of 60 HIV infected, HAART-experienced subjects currently receiving 3TC
(lamivudine, Epivir®) as part of their HAART therapy. The study will take place at
approximately 11 study sites in the US and Latin America.
The study is divided into four periods: a ‘Screening’ period which can last up to 30 days in
duration, a ‘Blinded Treatment’ period which can last up to 4 weeks in duration, a
‘Follow-up’ period which is 28 days in duration, and an ‘Open-label Treatment’ period that
some subjects will be given the option to participate in and which can last up to 20 weeks.
If eligible subjects decide to participate in this research study, they will be randomized,
which is like picking chances from a hat, to get RCV (Racivir®) alone, 3TC (lamivudine,
Epivir®) alone, or RCV and 3TC (lamivudine, Epivir®) in combination. This is a “double-blind
study”. This means that neither the subject nor the study doctor and study staff will know
if subjects are receiving RCV (Racivir®), 3TC (lamivudine, Epivir®), or RCV (Racivir®) and
3TC (lamivudine, Epivir®). This needs to be done to make sure the researchers obtain the
information needed to see if RCV (Racivir®) is safe and as effective as 3TC (lamivudine,
Epivir®). In case of an emergency, the study doctor will be able to find out immediately
what study drug subjects were receiving. With this exception, by signing the consent form
subjects agree that they will not be able to find out what medications they are taking,
because this is a “double-blind” study, it is necessary to use placebo tablets. A placebo is
a tablet that does not contain any active drug, but is made to look just like the study
drug.
Subjects will be given three bottles of study medication. They will be asked to take one
tablet from each bottle once a day by mouth, in addition to their current HAART drugs, not
including 3TC. The 3TC in their current HAART regimen must be discontinued prior to
beginning the study medication. It is important that subjects follow all directions when
taking the study drugs.
After completing the first 14 days of the blinded treatment period, subjects will be given
the option to continue on their current randomized therapy, including their current study
medication, for an additional 1-2 weeks. On Day 15, a blood sample will be collected to
determine the amount of HIV virus in the blood. Once the results from that blood sample are
available, subjects will be told the amount of how much HIV virus changed in the blood
during the first 14 days of treatment. Subjects will also be told if they were receiving RCV
(Racivir®) alone, 3TC (lamivudine, Epivir®) alone, or a combination of RCV (Racivir®) and
3TC (lamivudine, Epivir®).
If subjects were receiving RCV (Racivir®), to continue in the open-label treatment period,
the amount of virus in the blood must drop by at least 2/3 during the first 14 days of the
blinded treatment period. For example, if subjects enter the study with 10,000 copies of the
HIV virus per milliliter (ml) of blood, then to continue in the open-label period, the virus
level must drop to 3,162 copies or less, per ml of blood. Open-label means that
participating subjects and the study doctor or study staff will know what treatment subjects
were receiving.
If the virus drops by at least 2/3, subjects will be given the option to enter an open-label
treatment period. During the open-label period, subjects will receive 600 mg RCV (Racivir®)
once daily along with their regular HAART medications. Before entering the open-label
period, the study doctor may decide to change the subject's other ARV medications.
Participating subjects will be financially responsible for all medications, other than RCV
(Racivir®), that the study doctor may prescribe.
Once treatment is “unblinded”, subjects may learn that they were not receiving any RCV
(Racivir®) during the blinded treatment period. Subjects may voluntarily decide to add 600
mg RCV (Racivir®) once daily to the other HAART medications. The study doctor may decide to
change the subject's HAART medications at this time. After 2 weeks of RCV (Racivir®) based
treatment, subjects will be asked to return to the study doctor’s office to have blood drawn
to determine the amount of HIV virus in the blood. Subjects may continue on RCV (Racivir®)
for up to an additional 2 weeks until the results from the blood test are available. If the
viral load does not decline by at least 2/3, subjects will be withdrawn from the open-label
portion of the study. Subjects will be asked to return to the study doctor’s office for a
final follow-up visit approximately 28 days after the last dose of RCV (Racivir®).
The open-label treatment period will last no longer than 20 weeks. During this study,
subjects can receive up to 24 weeks of RCV (Racivir®) therapy. After subjects receive the
last dose of study medication, they will enter the follow-up period for 28 days.
If a participating subject or the study doctor decides to withdraw from the study early,
subjects will need to return to the study doctor’s office to have a follow-up visit
approximately 28 days after the last dose of RCV (Racivir®).
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |